Human papillomavirus in benign prostatic hyperplasia and prostatic adenocarcinoma patients.
The aim of this study was to determine the prevalence of human papillomavirus (HPV) types in tissue and HPV antibodies in prostatic disease. Prostate tissue samples were collected from 51 patients diagnosed with adenocarcinoma and 11 with benign prostatic hyperplasia (BPH). All tissue samples were confirmed by histology. Plasma samples were available for 52 prostate patients. We investigated HPV DNA prevalence by PCR, and PCR positive samples were HPV type determined by sequencing. Prevalence of antibodies against twenty-seven HPV proteins from fourteen different HPV types was assessed in the plasma samples. The HPV DNA prevalence in the tissue samples was 14% (7/51) for prostate cancer samples and 27% (3/11) for BPHs. HPV-18 was the only type detected in tissue samples (10/62). No significant difference in HPV prevalence between the prostate cancer and BPH samples was found. HPV-positive cells were identified in eight of our thirteen prostate tissue slides (3/3 BPH and 5/10 adenocarcinoma) by in situ hybridisation, and the positive cells were found in epithelial cells and peripheral blood cells. Serology data showed no significant increase in levels of antibodies against any of the HPV-18 proteins tested for in prostatic disease patients. Antibodies against HPV-1, HPV-4, HPV-6 and HPV-11 were significantly higher in the group of males with prostatic disease. Our study did not show an association between prostatic disease and either presence of HPV DNA in samples or previous exposure of high-risk HPV.
The University of Queensland, Diamantina Institute for Cancer, Immunology and Metabolic Medicine, Princess Alexandra Hospital, Brisbane, Australia.
Alice C-H
AC
Chen
Tim
T
Waterboer
Annie
A
Keleher
Beth
B
Morrison
Shalini
S
Jindal
Denise
D
McMillan
David
D
Nicol
Robert A
RA
Gardiner
Nigel A J
NA
McMillan
Annika
A
Antonsson
D000230:Adenocarcinoma / Q000150:complications / Q000473:pathology / Q000821:virology*; D000368:Aged; D000369:Aged, 80 and over; D004279:DNA, Viral / Q000097:blood / Q000235:genetics; D006801:Humans; D017403:In Situ Hybridization; D008297:Male; D008875:Middle Aged; D027383:Papillomaviridae / Q000235:genetics / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000209:etiology* / Q000473:pathology; D011379:Prognosis; D011470:Prostatic Hyperplasia / Q000150:complications / Q000473:pathology / Q000821:virology*; D011471:Prostatic Neoplasms / Q000150:complications / Q000473:pathology / Q000821:virology*; D015996:Survival Rate
D004279:DNA, Viral
J Gen Virol. 1999 Sep;80 ( Pt 9):2437-2443
10501499
Clin Chem. 2005 Oct;51(10):1845-53
16099939
J Urol. 1991 Apr;145(4):850-3
1848641
J Clin Oncol. 2007 Oct 10;25(29):4550-6
17925550
Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2374-81
18768506
J Natl Cancer Inst. 2006 Mar 1;98(5):303-15
16507827
Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):614-8
20142255
Prostate. 2002 Dec 1;53(4):263-76
12430138
Br J Cancer. 2005 Oct 17;93(8):946-8
16222323
Epidemiol Rev. 2001;23(1):144-51
11588840
Br J Cancer. 2009 Oct 20;101(8):1345-50
19724278
Endocr Rev. 1999 Feb;20(1):22-45
10047972
J Urol. 1992 Jan;147(1):192-6
1309581
Urology. 1997 Jul;50(1):150-6
9218040
Cancer Res. 1999 Feb 15;59(4):823-5
10029070
Saudi Med J. 2007 Mar;28(3):326-33
17334454
PLoS Pathog. 2008 Jun 20;4(6):e1000091
18566657
Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):872-5
14504197
Oncol Rep. 2003 Jan-Feb;10(1):175-9
12469166
Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78
8876633
J Gen Virol. 2008 Nov;89(Pt 11):2891-2897
18931088
Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):763-8
12917208
J Urol. 1993 Feb;149(2):400-2
7678873
Int J Urol. 2003 Feb;10(2):114-6
12588611